ANI Pharmaceuticals ANIP Rare Disease and Brands — Net Revenues

Similar metrics at other companies

BIIBRare Disease Product Revenue — Total Revenue

$557.2M-1.1%

HRMYRare Neurological Diseases — Revenue

$215.39M+16.6%

BMRNNet product revenues — Total revenues

$760.08M+3.5%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

HRMYRare Neurological Diseases — Net Income Loss

$32.49M-28.7%

VTRSBrands — Net Sales

$2.33B+10.2%

Questions, answered.

What is ANI Pharmaceuticals's rare disease and brands — net revenues?

ANI Pharmaceuticals (ANIP) reported rare disease and brands — net revenues of $128.24M in Q1 2026.

How has ANI Pharmaceuticals's rare disease and brands — net revenues changed year-over-year?

ANI Pharmaceuticals's rare disease and brands — net revenues increased by 36.3% year-over-year, from $94.08M to $128.24M.

What is the long-term trend for ANI Pharmaceuticals's rare disease and brands — net revenues?

Over 3 years (2022 to 2025), ANI Pharmaceuticals's rare disease and brands — net revenues has grown at a 81.3% compound annual growth rate (CAGR), from $81.15M to $483.93M.

What does rare disease and brands — net revenues mean?

Represents the total gross sales generated by the Rare Disease and Brands segment, adjusted for returns, allowances, and rebates. This metric serves as a primary indicator of market demand and commercial success for the company's specialized pharmaceutical portfolio.